My ePortfolio Register   

Novel treatment approaches in Ph like ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.01.17
Views: 236
Rating:

Dr Judith Boer – Erasmus Medical Centre - Sophia Children’s Hospital, Rotterdam, Netherlands

Dr Boer speaks with ecancer about the genetic subtypes of ALL, and how to best treat BCR-ABL-like patients.

She outlines the network of mutations that can drive leukaemia through JAK, ABL and RAS pathways, and describes Philidelphia-like genetic signatures.

Dr Boer also considers how druggable these pathways may be, including the use of tyrosine kinases.

For more on patient subtypes in ALL, click here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence